Complementary and alternative medicine use in asthma: Who is using what? von SLADER, Cassandra A., REDDEL, Helen K., JENKINS, Christine R., ARMOUR, Carol L., BOSNIC-ANTICEVICH, Sinthia Z.

Volltext

Measuring peak flow enhances adherence to monitoring in asthma von Slader, Cassandra A, Belousova, Elena G, Reddel, Helen K

Volltext

Lack of Awareness of Need to Clean CFC-Free Metered-Dose Inhalers von Slader, Cassandra A., Reddel, Helen K., Bosnic-Anticevich, Sinthia Z.

Volltext

Perceived Barriers by Hospital Pharmacists to Become Accredited to Perform Medication Reviews in the Home von Bennett, Alexandra (Sasha), Slader, Cassandra A

Volltext

Audit of Celecoxib and Rofecoxib Use: St Vincent's Public Hospital, Darlinghurst von Slader, Cassandra A, Welch, Susan A

Volltext

Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China von Maheshwari, Vikalp Kumar, Slader, Cassandra, Dani, Nidhi, Gkitzia, Christina, Yuan, Quan, Xiong, Tengbin, Liu, Yu, Viana, Ricardo

Volltext

Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China von Maheshwari, Vikalp Kumar, Slader, Cassandra, Dani, Nidhi, Gkitzia, Christina, Yuan, Quan, Xiong, Tengbin, Liu, Yu, Viana, Ricardo

Volltext

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study von Ross, David M., Branford, Susan, Seymour, John F., Schwarer, Anthony P., Arthur, Christopher, Yeung, David T., Dang, Phuong, Goyne, Jarrad M., Slader, Cassandra, Filshie, Robin J., Mills, Anthony K., Melo, Junia V., White, Deborah L., Grigg, Andrew P., Hughes, Timothy P.

Volltext

TARGET: a survey of real‐world management of chronic myeloid leukaemia across 33 countries von Turkina, Anna, Wang, Jianxiang, Mathews, Vikram, Saydam, Guray, Jung, Chul Won, Al Hashmi, Hani Hassan, Yassin, Mohamed, Le Clanche, Solenn, Miljkovic, Darko, Slader, Cassandra, Hughes, Timothy P.

Volltext

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized... von WHITE, Deborah L, RADICH, Jerald, MANLEY, Paul, SLADER, Cassandra, DONG WOOK KIM, PANE, Fabrizio, MARTINELLI, Giovanni, SAGLIO, Giuseppe, HUGHES, Timothy P, SOVERINI, Simona, SAUNDERS, Verity A, FREDE, Amity K, DANG, Phuong, CILLONI, Daniela, LIN, Peter, MONGAY, Lidia, WOODMAN, Richard

Volltext

A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer von Lu, Yen-Shen, Lee, Keun Seok, Chao, Tsu-Yi, Tseng, Ling-Ming, Chitapanarux, Imjai, Chen, Shin-Cheh, Liu, Chien-Ting, Sohn, Joohyuk, Kim, Jee Hyun, Chang, Yuan-Ching, Yang, Youngsen, Shotelersuk, Kanjana, Jung, Kyung Hae, Valenti, Roberta, Slader, Cassandra, Gao, Melissa, Park, Yeon Hee

Volltext

Do you hear us? Elevating the voice of patients from Asia Pacific (AP) and Middle East (ME) in pharmaceutical research von Rihani, Julie, Abdelbaky, Noha Mohamed Mahmoud, Gulabani, Chandra Rekha, Patel, Dexter, El Sayegh, Rami, Park, JungHo, Dinboeck, Michaela, Aubel, Dawn, Slader, Cassandra Alice

Volltext

Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey von Uhm, Jieun, Kim, Kyoung Ha, Lee, Hyewon, Kim, Hawk, Cassandra, Slader, Joo, Inkyung, Jung, Chul Won

Volltext

Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia von Viprakasit, Vip, Hamdy, Mona M., Hassab, Hoda M. A., Sherief, Laila M., Al-Bagshi, Muneer, Khattab, Mohammed, Chuncharunee, Suporn, Dung, Phu Chi, Küpesiz, Alphan, Shekhawat, Ankita, Sonawane, Yamini, Perez, Laura Torres, Slader, Cassandra, Taher, Ali T.

Volltext

Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON) von Memon, Muhammad A., Karaca, Burcak, Aboelhassan, Rasha, Barsoum, Mohsen, Erman, Mustafa, Basaran, Mert, Sevinc, Alper, Hanene, Djedi, Slader, Cassandra, Pilipovic, Virginia, Esma, Kerboua, Kamel, Bouzid

Volltext

Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients von Watkins, Dale B., Kok, Chung Hoow, Hughes, Timothy P., Slader, Cassandra, D'Andrea, Richard, White, Deborah L.

Volltext

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-... von White, Deborah L., Saunders, Verity A, Frede, Amity, GrootObbink, Kelvin, Slader, Cassandra, Yeung, David T., Osborn, Michael, Mills, Anthony K., Grigg, Andrew, Hughes, Timothy P

Volltext

Imatinib PK: Observations From the TIDEL II Study von White, Deborah L., Saunders, Verity, Andrew, Menelaou, Rofe, Allan, Slader, Cassandra, Yeung, David T., Osborn, Michael, Mills, Anthony K., Grigg, Andrew, Hughes, Timothy

Volltext

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A T... von White, Deborah L., Saunders, Verity, Frede, Amity, GrootObbink, Kelvin, Slader, Cassandra, Yeung, David T., Osborn, Michael, Mills, Anthony K., Grigg, Andrew, Hughes, Timothy

Volltext

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the... von Yeung, David T, Osborn, Michael Philip, White, Deborah L, Branford, Susan, Kornhauser, Michael, Slader, Cassandra, Issa, Samar, Hiwase, Devendra K., Hertzberg, Mark S., Schwarer, Anthony P., Filshie, Robin, Arthur, Christopher K, Kwan, Yiu Lam, Forsyth, Cecily J, Ross, David, Mills, Anthony K., Grigg, Andrew, Hughes, Timothy P.

Volltext